Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review
Open accessAbstract
Glucagon‐like peptide 1 receptor agonists (GLP‐1 RAs) reduce elevated blood glucose levels and induce weight loss. Multiple GLP‐1 RAs and one combined GLP‐1/glucose‐dependent insulinotropic polypeptide agonist are currently available. This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP‐1 RAs in individuals with type 2 diabetes (T2D), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health. This systematic review of PubMed and Embase from inception to early 2022 was registered on PROSPERO and was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses and Meta‐Analysis of Observational Studies in Epidemiology guidelines. Of the 740 records identified in the search, five studies fulfilled the inclusion criteria. Comparators included liraglutide, exenatide, dulaglutide and tirzepatide. In the identified studies, multiple dosing regimens were utilised for semaglutide. Randomised trials support the superior efficacy of semaglutide over other GLP‐1 RAs with respect to weight loss in T2D, but tirzepatide is more effective than semaglutide.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Semaglutide and tirzepatide have much larger impacts on weight and lean mass loss than liraglutide.
“Sema and Tz have much larger impacts on weight and LM loss than Lira (79).”
From Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (2024) · cites this paper as [79]
The Weight loss section reports significantly greater weight loss with semaglutide than with liraglutide, and greater weight loss with tirzepatide than with semaglutide, in the studied doses and patients with type 2 diabetes. It does not report lean-mass loss, so that part of the claim is unsupported. (LLM, conf=0.88)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817 · see citing works
Rayyan-a web and mobile app for systematic reviews.
Ouzzani, M., Hammady, H., Fedorowicz, Z., & Elmagarmid, A. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0384-4 · Cited by 26,092 · see citing works
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623 · see citing works
Page, M. J., Moher, D., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n160 · Cited by 11,883 · see citing works
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · see citing works
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · see citing works
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096 · see citing works
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · see citing works
Maintenance of Lost Weight and Long-Term Management of Obesity
Hall, K. D., & Kahan, S. (2018) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.08.012 · Cited by 876 · see citing works
O'Neil, P. M., Birkenfeld, A. L., McGowan, B., Mosenzon, O., Pedersen, S. D., Wharton, S., Carson, C. G., Jepsen, C. H., Kabisch, M., & Wilding, J. P. H. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31773-2 · Cited by 814 · see citing works
Pratley, R. E., Aroda, V. R., Lingvay, I., Lüdemann, J., Andreassen, C., Navarria, A., & Viljoen, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30024-x · Cited by 790 · see citing works
Ahmann, A. J., Capehorn, M., Charpentier, G., Dotta, F., Henkel, E., Lingvay, I., Holst, A. G., Annett, M. P., & Aroda, V. R. (2018) · Diabetes Care · doi:10.2337/dc17-0417 · Cited by 596 · see citing works
Pratley, R., Amod, A., Hoff, S. T., Kadowaki, T., Lingvay, I., Nauck, M., Pedersen, K. B., Saugstrup, T., & Meier, J. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31271-1 · Cited by 594 · see citing works
Reed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441 · see citing works
Body-Mass Index and Mortality among Adults with Incident Type 2 Diabetes
Tobias, D. K., Pan, A., Jackson, C. L., O’Reilly, É. J., Ding, E. L., Willett, W. C., Manson, J. E., & Hu, F. B. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304501 · Cited by 429 · see citing works
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Samms, R. J., Coghlan, M. P., & Sloop, K. W. (2020) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2020.02.006 · Cited by 419 · see citing works
Capehorn, M. S., Catarig, A.-M., Furberg, J. K., Janez, A., Price, H. C., Tadayon, S., Vergès, B., & Marre, M. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.101117 · Cited by 412 · see citing works
Glucagon-Like Peptide 1 Receptor Agonists for Type 2 Diabetes
Hinnen, D. (2017) · Diabetes Spectrum · doi:10.2337/ds16-0026 · Cited by 394 · see citing works
Nauck, M. A., Petrie, J. R., Sesti, G., Mannucci, E., Courrèges, J.-P., Lindegaard, M. L., Jensen, C. B., & Atkin, S. L. (2016) · Diabetes Care · doi:10.2337/dc15-0165 · Cited by 233 · see citing works
Yabe, D., Nakamura, J., Kaneto, H., Deenadayalan, S., Navarria, A., Gislum, M., Inagaki, N., Arisaka, T., Asakura, T., Azuma, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30074-7 · Cited by 210 · see citing works
Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes
Scheen, A. J., & Gaal, L. F. V. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(14)70004-x · Cited by 190 · see citing works
Gastrointestinal Symptoms in Diabetes: Prevalence, Assessment, Pathogenesis, and Management
Du, Y., Rayner, C. K., Jones, K. L., Talley, N. J., & Horowitz, M. (2018) · Diabetes Care · doi:10.2337/dc17-1536 · Cited by 182 · see citing works
Self-citationHorowitz, M., Flint, A., Jones, K. L., Hindsberger, C., Rasmussen, M. F., Kapitza, C., Doran, S., Jax, T., Zdravkovic, M., & Chapman, I. M. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.02.016 · Cited by 179 · see citing works
Ahrén, B., Atkin, S. L., Charpentier, G., Warren, M. L., Wilding, J. P. H., Birch, S., Holst, A. G., & Leiter, L. A. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13353 · Cited by 157 · see citing works
What is the relationship between risk factor reduction and degree of weight loss?
Gaal, L. F. V., Mertens, I. L., & Ballaux, D. (2005) · European Heart Journal Supplements · doi:10.1093/eurheartj/sui082 · Cited by 98 · see citing works
Type 2 diabetes via β-cell dysfunction in east Asian people
Yabe, D., & Seino, Y. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00389-7 · Cited by 77 · see citing works
Lingvay, I., Hansen, T., Macura, S., Marre, M., Nauck, M. A., de la Rosa, R., Woo, V., Yildirim, E., & Wilding, J. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001706 · Cited by 71 · see citing works
Weight changes following the initiation of new anti‐hyperglycaemic therapies
Nichols, G. A., & Gomez‐Caminero, A. (2006) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2006.00580.x · Cited by 66 · see citing works
Witkowski, M., Wilkinson, L., Webb, N., Weids, A., Glah, D. R., & Vražić, H. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0424-2 · Cited by 45 · see citing works
Flack, J. M., Mensah, G. A., & Ferrario, C. M. (2000) · Current Medical Research and Opinion · doi:10.1185/030079900542867 · Cited by 40 · see citing works
Flack, J. M., Mensah, G. A., & Ferrario, C. M. (2000) · Current Medical Research and Opinion · doi:10.1185/0300799009117011 · Cited by 40 · see citing works
Morris, E. M., Jebb, S. A., Oke, J. L., Nickless, A., Ahern, A. L., Boyland, E. J., Caterson, I. D., Halford, J. C. G., Hauner, H., & Aveyard, P. N. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x714113 · Cited by 36 · see citing works
Jalleh, R. J., Pham, H., Marathe, C. S., Wu, T., Buttfield, M., Hatzinikolas, S., Malbert, C., Rigda, R. S., Lange, K. M., Trahair, L. G., et al. (2020) · Nutrients · doi:10.3390/nu12071962 · Cited by 29 · see citing works
Self-citationManaging weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Blüher, M., Ceriello, A., Davies, M. J., Rodbard, H. W., Sattar, N. A., Schnell, O., Tonchevska, E., & Giorgino, F. (2022) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.330 · Cited by 19 · see citing works
Hashizume, M., Kinami, S., Sakurai, K., Izawa, K. P., & Shiotani, H. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16050812 · Cited by 11 · see citing works
Hospitals should improve their food culture and lead by example
Stretton, B., Kovoor, J. G., Gupta, A. K., et al. (2023) · BMJ · doi:10.1136/bmj.p37 · Cited by 7 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- [12]12. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283: 2008-12.
Cited by
Sorted by citations
Locatelli, J. C., Costa, J. G., Haynes, A., Naylor, L. H., Fegan, P. G., Yeap, B. B., & Green, D. J. (2024) · Diabetes Care · doi:10.2337/dci23-0100 · Cited by 152 · see citing works
- Authors
- Stretton, B., Kovoor, J., Bacchi, S., Chang, S., Ngoi, B., Murray, T., Bristow, T. C., Heng, J., Gupta, A., Ovenden, C., Maddern, G., Thompson, C. H., Heilbronn, L., Boyd, M., Rayner, C., Talley, N. J., & Horowtiz, M.
- Affiliations
- The University of Adelaide (AU)
- Griffith University (AU)
- Central Adelaide Local Health Network (AU)
- Gold Coast Hospital (AU)
- South Australian Health and Medical Research Institute (AU)
- Mayo Clinic (US)
- Royal Adelaide Hospital (AU)
- Corresponding author
- Stretton, Brandon
- ORCID
- Venue
- Internal Medicine Journal
- Publisher
- Wiley
- Published
- 2023-06-21
- Volume
- 53
- Issue
- 8
- Pages
- 1311-1320
- ISSN
- 1444-0903 (ISSN-L)
- 1445-5994
- OpenAlex
- W4376641692
- Cited by
- 26
- References
- 36
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 13
- FWCI
- 0.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Internal Medicine Journal (publishedVersion, other-oa)
- PubMed (publishedVersion)
- NOVA (University of Newcastle Australia) (submittedVersion)
- Funders
- University of Adelaide
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- semaglutide, GLP-1 receptor agonists, type 2 diabetes, weight loss, tirzepatide, liraglutide, exenatide, dulaglutide, head-to-head comparison, metabolic health
- MeSH terms
- Semaglutide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Weight Loss, Glucagon-Like Peptide 1, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
